Function Health
Widest diagnostic breadth at a consumer price point, anchored by Mark Hyman's brand and Quest's lab network
NOT CLEARED
No FDA clearance, registration, or CE marking found.
Key facts at a glance.
- Founded
- 2021
- Headquarters
- Austin, TX, USA
- Price range
- $365–$499
- App ratings
- iOS 4.7 · Android 4.3
The real price over three years.
Total cost of ownership · 3yr
| Hardwareone-time | $365 |
| 3-year total | $365 |
What the device does.
- + 100+ lab tests at enrollment across every major organ system
- + 60+ follow-up tests mid-year
- + Clinician review and personalized action plan
- + Dashboard with trends and food/supplement guidance
- + 2,000+ Quest Diagnostics draw locations nationwide
- + Co-founded by Dr. Mark Hyman (functional-medicine brand halo)
- + Add-on advanced tests (Galleri, APOE, etc.)
The trade-offs.
- + Densest biomarker panel in the category (110+ measured analytes per draw)
- + Lowest cost-per-biomarker (~$2.30/marker/draw at 2 draws/year)
- + Quest Diagnostics as CLIA/CAP-certified lab partner
- + Clean dashboard with longitudinal trend tracking
- + Growing physician network for result interpretation
- − $499/year is a significant commitment with no monthly option
- − No clinician consult included by default (unlike Lifeforce/SiPhox)
- − Active lawsuit against Superpower raises questions about competitive practices
- − Wait times for Quest appointments vary by region
- − AI-generated insights are generic — no personalized supplement/food recommendations (unlike InsideTracker)
Health-conscious adults and longevity enthusiasts wanting broad, twice-yearly clinician-reviewed bloodwork
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
Function Health launched with a bold premise: make comprehensive bloodwork accessible without a doctor’s visit. At $499/year for 2 draws of 110+ biomarkers each, it offers the densest panel in the direct-to-consumer space, processed through Quest Diagnostics’ CLIA/CAP-certified laboratories.
The 2026 context: Function filed suit against Superpower in January 2026, alleging that Superpower’s “100+ tests” marketing overstates measured biomarkers by counting calculated ratios. This lawsuit has become a category-defining moment — it’s why normalized biomarker counting matters in our comparisons.
Biomarker Coverage (Normalized)
We independently verified Function’s panel against their published test list:
- Measured analytes: 112 (unique tests sent to Quest)
- Calculated ratios: 8 (derived from measured values, not independent assays)
- Total marketed: “110+” (conservative vs competitors)
- Cost per measured biomarker: ~$2.23/marker/draw
This makes Function the value leader on a per-biomarker basis among full-panel services.
Lab Partner
Quest Diagnostics — CLIA-certified, CAP-accredited, the largest clinical lab network in the US. Sample collection at 2,200+ Quest patient service centers. This is the same lab infrastructure your physician uses.
What You Get
- Quarterly or semi-annual blood draws at Quest locations
- Dashboard with longitudinal biomarker trends
- Risk-flagging against clinical reference ranges
- Exportable PDF reports
- Not included: clinician interpretation, personalized supplement/diet recommendations, biological age scoring
3-Year Cost
| Component | Cost |
|---|---|
| Year 1 membership | $499 |
| Year 2 membership | $499 |
| Year 3 membership | $499 |
| 3-Year Total | $1,497 |
Compare: InsideTracker Ultimate ($589/yr × 3 = $1,767, ~60 biomarkers), Superpower ($468/yr × 3 = $1,404, ~65 verified measured biomarkers).
Verdict: Conditional
Function Health is the best value per biomarker in the category and the clearest dashboard for longitudinal tracking. The conditional verdict reflects the lack of included clinician interpretation and the absence of actionable lifestyle recommendations (where InsideTracker excels). If you want raw data density and trend tracking, Function wins. If you want a clinician to tell you what to do about the results, look at Lifeforce or SiPhox.
Changelog
- 2026-04-11: Initial review published. Biomarker count independently verified against published test list.
What we'll measure on the bench.
- Protocol
- CLIA/CAP service audit + biomarker-count verification
- Primary metric
- Biomarkers delivered vs marketed count
- Pass threshold
- within ±2 markers of marketing claim
- Session shape
- 1 kit ordered + 1 control retest
§ Bench session pending. Measured values will replace this panel as the protocol completes — see Plate VI · Methodology for the full testing rulebook.